NCT04447781View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

July 12, 2021

Study Completion Date

May 25, 2022

Conditions
Coronavirus InfectionSARS-CoV 2
Interventions
BIOLOGICAL

INO-4800

\- Manufacturer: Inovio Pharmaceuticals Inc.

DEVICE

CELLECTRA® 2000

\- Manufacturer: Inovio Pharmaceuticals Inc.

OTHER

Saline-sodium citrate (SSC) buffer

\- Manufacturer: Inovio Pharmaceuticals Inc.

Trial Locations (2)

13620

Seoul National University Bundang Hospital, Seongnam-si

03080

Seoul National University Hospital, Seoul

Sponsors

Collaborators (1)

Inovio Pharmaceuticals
All Listed Sponsors
collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

collaborator

Inovio Pharmaceuticals

INDUSTRY

lead

International Vaccine Institute

OTHER

NCT04447781 - Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19 | Biotech Hunter | Biotech Hunter